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Background. Cryptococcal meningitis is a leading cause of death in people living with human immunodeﬁcien-
cy virus (HIV)/acquired immune deﬁciency syndrome. The World Health Organizations recommends pre-antire-
troviral treatment (ART) cryptococcal antigen (CRAG) screening in persons with CD4 below 100 cells/µL. We
assessed the prevalence and outcome of cryptococcal antigenemia in rural southern Tanzania.
Methods. We conducted a retrospective study including all ART-naive adults with CD4 <150 cells/µL prospec-
tively enrolled in the Kilombero and Ulanga Antiretroviral Cohort between 2008 and 2012. Cryptococcal antigen was
assessed in cryopreserved pre-ART plasma. Cox regression estimated the composite outcome of death or loss to fol-
low-up (LFU) by CRAG status and ﬂuconazole use.
Results. Of 750 ART-naive adults, 28 (3.7%) were CRAG-positive, corresponding to a prevalence of 4.4% (23 of
520) in CD4 <100 and 2.2% (5 of 230) in CD4 100–150 cells/µL. Within 1 year, 75% (21 of 28) of CRAG-positive and
42% (302 of 722) of CRAG-negative patients were dead or LFU (P < .001), with no differences across CD4 strata. Cryp-
tococcal antigen positivity was an independent predictor of death or LFU after adjusting for relevant confounders (haz-
ard ratio [HR], 2.50; 95% conﬁdence interval [CI], 1.29–4.83; P = .006). Cryptococcal meningitis occurred in 39% (11 of
28) of CRAG-positive patients, with similar retention-in-care regardless of meningitis diagnosis (P = .8). Cryptococcal
antigen titer >1:160 was associated with meningitis development (odds ratio, 4.83; 95% CI, 1.24–8.41; P = .008). Flu-
conazole receipt decreased death or LFU in CRAG-positive patients (HR, 0.18; 95% CI, .04–.78; P = .022).
Conclusions. Cryptococcal antigenemia predicted mortality or LFU among ART-naive HIV-infected persons with
CD4 <150 cells/µL, and ﬂuconazole increased survival or retention-in-care, suggesting that targeted pre-ART CRAG
screening may decrease early mortality or LFU. A CRAG screening threshold of CD4 <100 cells/µL missed 18% of
CRAG-positive patients, suggesting guidelines should consider a higher threshold.
Keywords. cryptococcal antigen; cryptococcal meningitis; diagnosis; mortality; prevention; retention in care;
screening; sub-Saharan Africa.
Cryptococcus neoformans is a major cause of adult men-
ingitis in sub-Saharan Africa and a leading cause of
mortality among people living with human immunode-
ﬁciency virus (PLHIV) [1, 2]. Cryptococcal meningitis
Received 14 January 2015; accepted 30 March 2015.
aE. L., M. C. M., D. R. B., and T. R. G. contributed equally to this work.
Presented in part: 21st Conference on Retroviruses and Opportunistic Infections,
Boston, MA.
Correspondence: Emilio Letang, MD, MPH, PhD, Swiss Tropical and Public
Health Institute (Swiss TPH), Socinstrasse 57, 4051 Basel, Switzerland (emili.
letang@unibas.ch).
Open Forum Infectious Diseases
© The Author 2015. Published by Oxford University Press on behalf of the Infectious
DiseasesSocietyofAmerica. This is anOpenAccessarticledistributedunder the terms
of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://
creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial
reproduction and distribution of the work, in any medium, provided the original work
is not altered or transformed in any way, and that the work is properly cited. For
commercial re-use, please contact journals.permissions@oup.com.
DOI: 10.1093/oﬁd/ofv046
CRAG Prevalence and Outcome in Rural Tanzania • OFID • 1
(CM) is estimated to cause 13%–44% of HIV/acquired immune
deﬁciency syndrome (AIDS) deaths in Africa [1, 3] and is a major
contributor of early mortality during the ﬁrst year of antiretro-
viral treatment (ART), accounting for up to 20% of all deaths
[4, 5].Treatment of cryptococcosis is suboptimal in most African
settings, given the low availability of ﬁrst-line antifungal drugs
and low uptake of recommendations for management of intra-
cranial pressure. As a result, cryptococcal-related mortality in
Africa remains unacceptably high, ranging from 20% to 50%
even in settings with available ﬁrst-line drugs [6–10].
Early diagnosis of cryptococcal infection is the key to improv-
ing outcomes. Detectable cryptococcal antigen (CRAG) in pe-
ripheral blood precedes meningitis symptoms by weeks to
months, opening a window of opportunity for early detection
[3]. The World Health Organization (WHO) recommends
pre-ART-targeted plasma CRAG screening for PLHIV with
CD4 <100 cells/µL followed by preemptive ﬂuconazole treat-
ment in regions with high incidence of CRAG [11].
Data about the burden of cryptococcal disease in Tanzania
are scarce. In a retrospective study in Dar es Salaam, analyzing
1144 cerebrospinal ﬂuids (CSFs) specimens, Cryptococcus neo-
formans accounted for 98% of all positive CSF cultures among
adults and 22% among children [12]. In another study in the
Kilimanjaro region in 2005/2006, 27% (40 of 149) of consecu-
tive HIV-infected adult inpatients presenting with headache or
altered mental status were diagnosed with cryptococcal menin-
gitis [13]. A study conducted in Mwanza, in northwestern
Tanzania in 2009/2010, showed a 5% prevalence of CRAG by
latex agglutination and 4.4% prevalence of cryptococcal menin-
gitis among 333 PLHIV consecutively admitted in a medical
ward [14]. Among the 93 patients with CD4 counts <100
cells/µL, the cryptococcal meningitis prevalence was 15%, and
Cryptococcus accounted for 26% of all in-hospital deaths. A
more recent cross-sectional study, aiming to evaluate the per-
formance of CRAG lateral ﬂow assay (LFA) in the Kilimanjaro
region, showed a 5% prevalence among PLHIV with CD4 cell
counts <100 cells/µL [15].
Taken together, these ﬁndings suggest that cryptococcosis is
common among PLHIV in Tanzania and an important cause of
preventable mortality. Aiming to explore the potential impact of
the WHO recommendations on CRAG screening in Tanzania,
we assessed the prevalence of CRAG and impact on survival
and retention-in-care among a cohort of ART-naive PLHIV en-
gaged in care between 2008 and 2012.
METHODS
Study Design and Setting
All data were prospectively collected from participants enrolled
in the Kilombero and Ulanga Antiretroviral Cohort (KIULAR-
CO). This ongoing, open, prospective cohort comprises all pa-
tients who visit the Chronic Diseases Clinic of Ifakara within
the Saint Francis Referral Hospital and provide their written in-
formed consent. This is the largest healthcare facility in the Kil-
ombero district of the Morogoro region in southern Tanzania,
providing treatment and care for a population of approximately
600 000 inhabitants and an estimated 30 000 patients living
with HIV/AIDS. Established in 2004, this was the ﬁrst rural
clinic accredited to be a Care and Treatment Centre of the Na-
tional AIDS Control Program in the whole of Tanzania, and
>7000 patients have been enrolled into care. Blood samples
are drawn at routine clinic visits before, 2 weeks and 3 months
after ART initiation, and every 6 months thereafter. Plasma is
cryopreserved at −80°C. Further details of the KIULARCO co-
hort are given elsewhere [16, 17].
Participants
We included all ART-naive patients >18 years-old of age en-
rolled in KIULARCO between January 1, 2008 and December
31, 2012 with CD4 counts <150 cells/µL who had an available
cryopreserved pre-ART sample.
Cryptococcal Antigenemia Testing and TitrationCryptococ-
cal antigenemia LFA (IMMY, Inc., Norman, OK) was per-
formed according to the manufacturer’s instructions in the
most recent stored plasma sample collected within a maximum
of 90 days before ART initiation. Semiquantitative LFA CRAG
titers were measured in all CRAG-positive samples using 2-fold
dilutions, as per the manufacturer’s instructions.
CD4 Counting
CD4 counts were measured after staining fresh whole blood
samples with labeled antibodies: CD4, CD3, CD8, and CD45 in
TruCount tubes (BD FACSCalibur, Franklin Lakes, NJ, U.S.A).
Statistical Analysis
All data were extracted from the electronic databases of the
KIULARCO cohort. In addition, for patients with a positive
CRAG test, medical records were reviewed for medication use,
presenting symptoms, and follow-up status or cause of death.
The baseline was deﬁned as the date of the pre-ART CRAG
assessment. The time from baseline to the combined endpoint
of death or LFU within 1 year was investigated. The time of the
event was deﬁned as the day of the last follow-up visit docu-
mented in the database within 1 year of follow-up. Patients
who experienced an event after 1 year from baseline or were
still retained-in-care were right-hand censored at 1 year. Log-
rank test was used to compare the risk of developing the out-
come of death or LFU by CRAG status.
Multivariate Cox proportional hazards models assessed the as-
sociation between pre-ARTCRAG status and death or LFU with-
in 1 year from baseline. The following variables were considered a
priori as potential cofactors or confounders and were included in
the multivariate model: age, sex, body mass index (BMI), CD4
cell count, ART status, WHO stage (Stage 1/2 vs 3/4), and
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tuberculosis (TB) status (suspected, on treatment, microscopy
sputum smear positive vs no TB). Assumption of proportional
hazards was conﬁrmed by Schoenfeld’s global test (P = .3).
In a subgroup analysis of asymptomatic CRAG-positive par-
ticipants, we evaluated the contribution of ﬂuconazole to sur-
vival or retention-in-care using Cox proportional hazards
models to assess the association between baseline variables
and a combined endpoint of death or LFU within 1 year. Final-
ly, the CRAG titer was analyzed for the presence of a threshold
predicting the future development of cryptococcal meningitis,
with statistical assessment by logistic regression.
All data were anonymized and analyzed using STATAversion
12.1 (Stata Statistical Software, StataCorp, College Station, TX).
Ethics Statement
Written informed consent was sought from all participants at
registration at the Chronic Diseases clinic of Ifakara, and all
data were deindentiﬁed. Samples were collected during routine
clinical visits, and ethical approval for its cryopreservation and
retrospective analysis was obtained from the Ifakara Health In-
stitute institutional review board and from the National Health
Research Ethics Review Committee of the National Institute for
Medical Research of Tanzania.
RESULTS
Cohort Characteristics
A total of 750 ART-naive HIV-1-infected adults were included in
the study (Figure 1). Table 1 summarizes the pre-ART baseline
characteristics by CRAG status. Overall, 60% of participants
were women with a median age at enrollment of 38.3 years (inter-
quartile range [IQR], 32.5–45.2). Median BMI was 19.8 kg/m2
(IQR, 17.7–22.1), and median CD4 was 71 cells/µL (IQR, 36–
109). Cryptococcal antigenemia-positive patients had lower CD4
cell counts, lower BMI, and had a higher proportion of WHO
stage III/IV and males. Eighty-eight percent of patients started
ART, with a median time of 5 days (IQR, 1–11) after enrollment.
Prevalence and Characterization of Cryptococcal Antigenemia
The 750 participants enrolled contributed 488 person-years of
follow-up time during the study period. Overall, 28 of 750 pa-
tients (3.7%; 95% conﬁdence interval [CI], 2.4–5.1) had a pos-
itive CRAG LFA in plasma. CD4 stratum-speciﬁc CRAG
prevalence was 6.3% (17 of 270; 95% CI, 3.4–9.2%) in CD4
<50, 4.4% (23 of 520; 95% CI, .5–4.3) in CD4 <100, and 2.2%
(5 of 230; 95% CI, .3–4.1) in CD4 100–150 cells/µL. Overall,
18% of CRAG-positive persons had CD4 > 100 cells/µL (95%
CI, 6.1%–37%). The median pre-ART CRAG LFA titer was
1:320 (IQR, 1:20–1:2560) (Supplementary Table).
Outcome and Predictors of Death or Loss to Follow-Up
Of 28 CRAG-positive persons, 21 (75%) died or were lost com-
pared with 302 of 722 (42%) CRAG-negative persons within the
ﬁrst year (P = .001; Figure 2A). This proportion was similar
across CD4 strata, being 76.5% (13 of 17), 83% (5 of 6), and
60% (3 of 5) among patients with ≤50, 51–100, and 101–150
CD4 cells/µL, respectively (P = .656). The median survival
time in CRAG-positive patients was 3.0 months (IQR, 0.5–
6.82) compared with 12.0 months (IQR, 1.6–12.0; P = .001)
for CRAG-negative patients. Eighty-nine percent (25 of 28) of
CRAG-positive persons initiated ART.
Baseline risk factors for death or LFU are presented in
Table 2. The CRAG-positive status was found to be an indepen-
dent predictor of increased risk of death or LFU compared with
CRAG-negative status after adjusting for all prespeciﬁed con-
founders (HR, 2.50; 95% CI, 1.29–4.83; P = .006). Additional
variables found to be signiﬁcantly associated with death or
LFU were not having initiated ART (HR, 2.25; 95% CI, 1.03–
4.88; P = .041) and female gender (HR, 1.50; 95% CI, 1.05–
2.15; P = .025). Protective factors were older age (HR, 0.73 per
10 years increase; 95% CI, .60–.90; P = .003) and higher BMI
(HR, 0.9 per kg/m2 increase; 95% CI, .85–.95; P < .001). Higher
CD4 counts were protective from death or LFU in univariable
but not in multivariable analyses (Table 2).
Predictors of Cryptococcal Meningitis and Mortality/Loss to
Follow-Up Among Cryptococcal Antigenemia-Positive Patients
Seven CRAG-positive patients (25%) were recorded to have pre-
sented at baseline with pre-ART neurologic symptoms (eg, head-
ache n = 7, suspected meningitis n = 1), and 4 of 21 (19%)
initially neurologically asymptomatic patients developed menin-
gitis at a median of 6 weeks (range, 1 −16 weeks) after starting
ART. In total, 39% (11 of 28) of CRAG-positive patients were
recorded to have neurological symptoms, and 9 were diagnosed
clinically with cryptococcal meningitis during follow-up.Figure 1. Study proﬁle of included and excluded participants.
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The risk of developing meningitis among the 21 initially
asymptomatic CRAG-positive patients was signiﬁcantly associ-
ated with a CRAG titer > 1:160 in a multivariable logistic
regression model, adjusted by CD4, gender, and age (odds ratio,
4.83; 95% CI, 1.24–8.41; P = .008). None of the 11 patients with
an antigen titer of ≤1:160 developed symptoms of meningitis.
Table 1. Baseline Characteristics of Study Populationa
Variable Total CRAG– CRAG+
N 750 722 28
Age, years - median (IQR) 38.3 (32.5–45.2) 38.3 (32.3–45.2) 36.7 (33.6–44.8)
Female 448 (60%) 436 (60%) 12 (43%)
BMI, kg/m² - median (IQR) 19.8 (17.7–22.1) 19.9 (17.7–22.1) 18.7 (17.5–19.7)
WHO - stage 3 or 4 297 (45%) 283 (45%) 14 (56%)
CD4 cells/μL - median (IQR) 71 (36–109) 71 (36–110) 37 (19–76)
Stratum 0–50 cells/μL 270 (36%) 253 (35%) 17 (61%)
Stratum 51–100 cells/μL 250 (33%) 244 (34%) 6 (21%)
Stratum 101–150 cells/μL 230 (31%) 225 (31%) 5 (18%)
CRAG titer, median (IQR) 320 (20–2560)
Stratum 1:5–1:20 . . . . . . 8 (29)
Stratum 1:40–1:1280 . . . . . . 12 (43)
Stratum 1:2560–1:10240 . . . . . . 8 (29)
Hospitalized . . . . . . 9 (32%)
Fluconazole treatment . . . . . . 13 (46%)
Time to start ART, days - median (IQR) 5 (1–11) 5 (1–11) 1 (1–5)
Did not initiate ART 90 (12%) 87 (12%) 3 (11%)
Neurologic symptoms at baseline . . . . . . 7 (25%)
Active tuberculosis 77 (12%) 73 (12%) 4 (20%)
Abbreviations: ART, antiretroviral treatment; BMI, body mass index; CRAG, cryptococcal antigenemia; IQR, interquartile; WHO, World Health Organization.
a Data are presented as n (%) or median (IQR).
Figure 2. Left graph (A): Kaplan–Meier survival estimates of death or loss to follow-up by pre-antiretroviral treatment (ART) cryptococcal antigenemia (CRAG)
status. Right graph (B): Time to death or loss to follow-up among CRAG-positive persons versus ﬂuconazole receipt, adjusted by ART status and CD4 cell count.
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Three of these patients died of unknown causes with an average
time of 3.4 months after baseline.
A subanalysis was conducted to explore the contribution of
ﬂuconazole to survival or retention-in- care among the 21 neu-
rologically asymptomatic CRAG-positive patients. Thirty-eight
percent (8 of 21) of patients received ﬂuconazole (100–200 mg/
day) as per physician discretion, mostly for oral thrush (6 of 8).
Among 8 CRAG-positive persons receiving any ﬂuconazole, the
median survival time was 6.5 (IQR, 2.4–12.0) months with 50%
(4 of 8) 1-year survival. In contrast, only 2 of 13 persons (15%)
survived 1 year among those CRAG-positive persons not receiv-
ing any ﬂuconazole, with a median survival time of 1.6 (IQR,
0.5–4.8) months (P = .155). After adjusting for CD4 cell count
and ART status, receiving any ﬂuconazole treatment reduced
the hazard for death or LFU by 82% (95% CI, 22%–96%;
P = .022) during the ﬁrst year of follow-up (Table 3; Figure 2B).
DISCUSSION
Cryptococcal antigenemia was prevalent and an indepen-
dent predictor of death or LFU in our cohort of ART-naive
HIV-infected patients with a CD4 cell count <150 cells/µL in
rural Tanzania. The development of signs compatible with
cryptococcal meningitis among initially asymptomatic CRAG-
positive patients was associated with CRAG LFA titers >1:160 in
plasma. Fluconazole, given incidentally as per physician discre-
tion, most commonly for thrush, reduced the hazard of death
or LFU in CRAG-positive persons. These results further sup-
port the implementation of a systematic CD4-targeted CRAG
screening followed by preemptive treatment with ﬂuconazole
for CRAG-positive patients, as recommended by WHO and
U.S. President’s Emergency Plan for AIDS Relief [11]. However,
our results suggest reconsidering the CD4 threshold for CRAG
screening, because 18% of CRAG-positive patients had a mea-
sured CD4 cell count >100 cells/µL along with a similarly high
rate of poor survival.
We found a CRAG prevalence of 3.7% among ART-naive
persons with a CD4 cell counts of <150 cells/µL, 4.4% among
those with <100 cells/µL, and 6.7% among <50 cells/µL, com-
parable with other countries in sub-Saharan African settings
[15, 18–21]. Cryptococcal antigenemia prevalence among those
patients with CD4 counts between 100 and 150 cells/µL was
2.2% (95% CI, .3%–4.1%)
At this prevalence, the WHO CRAG screen and treat strategy
would be cost saving in Tanzania compared with the cost of cryp-
tococcal meningitis treatment [21, 22]. Due to the lower costs of
CRAG LFA (USD 2/test), CRAG screening is cost-effective and
likely cost-saving at a CRAG prevalence of ∼1% [21, 23]. There
are approximately 125 000 HIV-infected Tanzanians with CD4
<125 cells/µL not receiving effective ART [24]. Based on the
Table 2. Association With Death or Loss to Follow Up by 1 Year, Using a Cox Regression Model Among All Persons With CD4 <150 Cells/µL
Variables
Unadjusted/Univariate Model
Adjusted/Multivariate Model
(n = 137 Events)
HR (95% CI) P Value HR (95% CI) P Value
CRAG+ 2.43 (1.50–3.92) <.001 2.50 (1.29–4.83) .006
Age, per 10 years 0.96 (.86–1.09) .553 0.74 (.60–.90) .003
Female 1.42 (1.12–1.80) .004 1.50 (1.05–2.14) .025
Body mass index, per kg/m² 0.88 (.84–.93) <.001 0.90 (.85–.95) <.001
CD4 cell count, per 25/μL 0.87 (.81–.93) <.001 0.93 (.84–1.04) .205
Tuberculosis 1.38 (.96–1.99) .080 1.19 (.72–1.97) .505
No ART 3.79 (2.67–5.40) <.001 2.25 (1.03–4.88) .041
Abbreviations: ART, antiretroviral treatment; CI, confidence interval; CRAG, cryptococcal antigenemia; HR, hazards ratio.
Table 3. Association With Death or Loss to Follow Up by 1 Year, Using a Cox Regression Model Among 21 Asymptomatic CRAG-Positive
Persons With CD4 <150 Cells/CD4 Cells >100 cells/µL
Variables
Unadjusted/Univariate Model
Adjusted/Multivariate Model
(n = 14 Events)
HR (95% CI) P Value HR (95% CI) P Value
CD4 cells >100 cells/μL 0.64 (.14–2.86) .556 0.28 (.05–1.50) .137
No ART 2.41 (.53–11.13) .256 1.05 (.21–5.21) .955
Fluconazole treatment 0.28 (.08–1.04) .051 0.18 (.04–.78) .022
Abbreviations: ART, antiretroviral treatment; CI, confidence interval; CRAG, cryptococcal antigenemia; HR, hazards ratio.
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data herein, approximately 5000 CRAG-positive Tanzanians an-
nually would potentially beneﬁt from having access to pre-ART
CRAG LFA screening (testing cost = $250 000). High-burden
countries, such as Tanzania, should prioritize reliable access to
this CRAG LFA test and the implementation of the WHO
screening recommendations to enable early diagnosis of crypto-
coccal infection and improve survival.The optimal CD4 screen-
ing threshold remains unknown. In our cohort, 18% of all
CRAG-positive persons had CD4 counts >100 cells/µL, with 4
of 5 between 100 and 125 cells/µL. This proportion of CRAG-
positive patients with a CD4 cell count >100 cells/µL lies at the
upper end of published data, which ranges from 1% to 21%
[25–28]. Setting the CRAG-screening threshold at 125 CD4
cells/µL would capture 96% of CRAG-positive persons in our
population. Unlike the published outcomes experience in Ugan-
da [25], the survival outcome in patients with CD4 >100 cells/µL
did not differ from those with CD4 <100 CD4 cells/µL, although
the sample size was small. Of note, the only two 1-year survivors
who were CRAG-positive and untreated with ﬂuconazole in our
study had CD4 >100 cells/µLl Thus, based on resources available
and accuracy of CD4 testing, the threshold for screening may
need to be raised to CD4 125 cells/µLl.
Among initially asymptomatic CRAG-positive persons, the
development of cryptococcal meningitis was associated with
the CRAG titer in plasma. Having a CRAG LFA titer >1:160
was associated with an approximately 5-fold increase in the
odds of developing meningitis, and none of the patients with a
CRAG titer ≤1:160 developed meningitis. However, 3 of these
patients died of unknown reasons, and we cannot exclude cryp-
tococcosis as the cause of death. Using this cutoff titer would have
required 1 single additional CRAG LFA test per patient. Thus, for
the screening of 750 patients, 28 additional test strips would have
been needed to determine whether the CRAG titer was above or
below the breakpoint, with an additional cost of approximately
$56.00 per 750 screened patients, $0.07 per patient screened.
Our results support the ﬁndings of a study showing differences
in CRAG titer between CRAG-positive patients with and without
proven meningitis (1:128 to 1:1024 vs 1:8 to 1:128, respectively).
Likewise, in another study conducted in South Africa [29], using
a cutoff CRAG titer of 1:8 by latex agglutination (equivalent to
approx. 1:40 titer by LFA LA screening [30]) had 100% sensitivity
and 96% speciﬁcity for predicting incident CM among all pa-
tients with CD4 counts <100 cells/µL. In asymptomatic CRAG-
positive patients with low CRAG titers, ﬂuconazole alone without
lumbar puncture may be sufﬁcient for treatment. Although the
speciﬁc CRAG titer cutoff remains uncertain, it may be approx-
imately 1:100 (or within ±2-fold dilution thereof). Our results
warrant further validation in larger studies.
Receiving any dose of ﬂuconazole during follow-up given
incidentally at physician discretion signiﬁcantly improved
survival and retention-in-care within the ﬁrst year (50% vs
8% without ﬂuconazole). A reduction in mortality due to
ﬂuconazole treatment was also seen in a noncontrolled observa-
tional study by Meya et al [25], in which low-dose ﬂuconazole
treatment of asymptomatic CRAG-positive persons resulted in
a 76% 5-year survival vs 0% 4-month survival without ﬂucon-
azole treatment [31]. In a Cambodian CRAG study, 80% (8 of
10) survival occurred with ﬂuconazole at 200 mg/day with no
deaths related to meningitis [28]. Another study done in Thai-
land showed 100% survival in asymptomatic CRAG-positive
patients given preemptive ﬂuconazole [26]. These data suggest
that even low-dose ﬂuconazole treatment may lower early mor-
tality in asymptomatic CRAG-positive PLHIV initiating ART
and further supports the need for implementing a systematic
screening followed by preemptive ﬂuconazole treatment in Tan-
zania and other African countries. Again, these results should
be interpreted with caution due to the limited sample size.
This study has several limitations. First, although clinical data
were collected prospectively, we conducted retrospective CRAG
testing of cryopreserved plasma samples. Of note, physicians
managing these cases were unaware of the CRAG result, because
CRAG LFAwas not available in our facility before 2013. Medical
records of CRAG-positive patients were then reviewed to retrieve
additional data on symptoms and management. Based on these
records, 11 of 28 CRAG-positive patients presented with neuro-
logic symptoms either pre-ART (n = 7) or after ART initiation
(n = 4), of whom 9 were clinically diagnosed with cryptococcal
meningitis. Indeed, the outcomes between symptomatic and
asymptomatic CRAG-positive patients did not seem to be differ-
ent, reinforcing that asymptomatic CRAG-positive patients who
do not receive antifungal therapy will eventually die. Second, ﬂu-
conazole was given as per physician criteria, mostly for other con-
ditions such as oral thrush or tinea with different doses and
treatment duration. This limits any possible conclusion from
our data beyond the recognition that having received any ﬂucon-
azole improved survival or retention-in-care. In addition, due to
a suboptimal ascertainment of mortality in our cohort, we had to
use a composite outcome of death or LFU, limiting our conclu-
sions regarding the impact of CRAG screening and ﬂuconazole
treatment on mortality. However, considering the low CD4
counts of our study population, it is likely that the majority of
those lost actually died [32]. There was incomplete ascertainment
on the cause of death. Therefore, the characterization of the
course of untreated CRAG was limited to the proportion of
those who were clinically diagnosed with cryptococcal meningitis
and those who died of any cause or were loss to follow-up. Final-
ly, as already mentioned, the subanalysis performed among
CRAG-positive patients should be interpreted with caution due
to the low sample size.
There are several implications of our ﬁndings. First, there is a
need to raise awareness about the prevalence and high mortality
associated with CRAG in Tanzania and other sub-Saharan Af-
rican countries. The CRAG prevalence found in our study jus-
tiﬁes the adoption of the WHO recommendations on CRAG
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screening in Tanzania, which would be cost-effective at this
prevalence based on previous studies [21, 23].Moreover, the ob-
served improved outcomes among patients that received ﬂucon-
azole further justify the implementation of this low-cost, simple
recommendation. Optimal ﬂuconazole dosing is unknown [11].
However, the observation of similarly poor outcomes of the
CRAG-positive patients who had measured CD4 counts >100
cells/µL raises concerns about what is the optimal CD4 thresh-
old for CRAG screening. Although data on CRAG prevalence
and outcome of CD4 >100 cells/µL is still limited, our results
may support increasing the CD4 threshold to 125 or 150
cells/µL. Finally, we observed that CRAG-positive patients
with low CRAG titers did not develop meningitis, which sug-
gests a potential role of using titers for risk stratiﬁcation among
asymptomatic CRAG-positive patients.
CONCLUSIONS
In summary, CRAG was prevalent and an independent predic-
tor of early mortality on ART. Three-quarters of CRAG+
patients died within 1 year. This unacceptably high mortality
needs to be urgently addressed, and it could be easily prevented
by increasing access to CRAG LFA and adopting the CRAG-
screening guidelines recommended by the WHO for high-
burden countries.
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(http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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